Skip to content
Psychedelics are a new tool for the mental health space, a new technology if you will. But as with any new technology, there exists a peak of expectation, followed by a trough of disillusionment, before the plateau of efficacy emerges. Come hear a sober view on what we’ve seen since the rise in mainstream coverage as well as what this means for the future.

Details

  • Second Stage
Date:
11/03/2022
Start Time:
2:55 pm
End Time:
15:35

Ashley Southard

Founder/CEO, Mushroom Design

Ashley is a founder, CEO, and COO of companies supporting People + Planet via for-profit and non-profit ventures in the nutraceutical, mental health, and wellness sectors, including psychedelic medici…

Dr. Julia Mirer, MD

Director of Strategy & Impact, Nushama, Psychedelic Medicine Coalition

Dr. Julia Mirer MD is a consultant in the emerging field of psychedelic medicine, serving as a bridge between Eastern and Western practices, committed to merging the two in order to help create a new …

Dina Burkitbayeva

CEO, PsyMed Ventures, Freedom Biosciences

Dina Burkitbayeva is the co-founder & CEO of Freedom Biosciences, a clinical stage biotech platform developing next generation psychedelic therapeutics. Dina is also the co-founder of PsyMed Ventures,…

Dr. Sarah Abedi, MD

Clinical Research Facilitator and Co-Founder of Onea, Pacific Neuroscience Institute/Onea/Veterans Affairs Psychedelic Research & Education Center (VAPREC), Onea Health

Sarah Abedi is an emergency medicine physician and psychedelic facilitator at Pacific Brain Health’s Treatment & Research In Psychedelics Program (TRIP). She is also a part of the founding team and fa…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.

Buy Now